NLRC4 and neoplasm: Its excellent anti-tumor activity can be attributed to inflammasome release such as nucleotide binding domain, leucine rich containing, pyrin domain containing (NLRP3) and ice protease activating factor (IPAF, also referred to as NLRC4) which induces the expression of proinflammatory cytokines, interleukins (IL-1β, IL-18) and TNF-α and consequently, causes tumor regression.